Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation with an Intramedullary Nail - Study To Assess Healing of Repaired Tibias with SclerosTin Antibody (STARTT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Romosozumab (Primary)
- Indications Fracture
- Focus Therapeutic Use
- Acronyms STARTT
- Sponsors Amgen
- 03 Sep 2014 New trial record